Theravance, Mylan settle patent litigation with Teva over Yupelri
Teva has been granted a royalty-free, non-exclusive license to market generic Yupelri in the United States on or after April 23, 2039.
Theravance and its partner Mylan have granted Teva a royalty-free, non-exclusive license to market a generic version of Yupelri in the United States on or after April 23, 2039, as part of a settlement of their patent litigation, according to an SEC filing on Monday.
Yupelri (revefenacin), is used to treat patients with COPD.
A lawsuit had been filed by Theravance and Mylan against Teva for its efforts to market generic Yupelri, prior to the drug's Orange Book-listed patents had expired.
[Read more: Challenges continue, but generics companies see a bright future with biosimilars
The agreement is subject to Department of Justice and Federal Trade Commission approval, per the filing.